Stock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates

Stock Track

07/30

Alnylam Pharmaceuticals (ALNY) shares tumbled 7.45% in pre-market trading on Thursday after the company reported second-quarter revenue that fell short of analyst expectations.

The biotech firm posted revenue of $1.29 billion for the quarter, missing the consensus estimate of $1.323 billion according to Ibes data. The top-line miss appeared to overshadow the company's operating income figures, which were also released alongside the revenue report.

Investors reacted swiftly to the shortfall, driving the stock sharply lower in early trading. The decline highlights the market's sensitivity to revenue growth metrics for high-valuation biotech companies like Alnylam.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1184756636"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184756636\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184756636?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184756636","market":"sg","top_or_hot":-1,"title":"Stock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates","media":"Stock Track","content":"<p>Alnylam Pharmaceuticals (ALNY) shares tumbled 7.45% in pre-market trading on Thursday after the company reported second-quarter revenue that fell short of analyst expectations.</p><p>The biotech firm posted revenue of $1.29 billion for the quarter, missing the consensus estimate of $1.323 billion according to Ibes data. The top-line miss appeared to overshadow the company's operating income figures, which were also released alongside the revenue report.</p><p>Investors reacted swiftly to the shortfall, driving the stock sharply lower in early trading. The decline highlights the market's sensitivity to revenue growth metrics for high-valuation biotech companies like Alnylam.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-30 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alnylam Pharmaceuticals (ALNY) shares tumbled 7.45% in pre-market trading on Thursday after the company reported second-quarter revenue that fell short of analyst expectations.</p><p>The biotech firm posted revenue of $1.29 billion for the quarter, missing the consensus estimate of $1.323 billion according to Ibes data. The top-line miss appeared to overshadow the company's operating income figures, which were also released alongside the revenue report.</p><p>Investors reacted swiftly to the shortfall, driving the stock sharply lower in early trading. The decline highlights the market's sensitivity to revenue growth metrics for high-valuation biotech companies like Alnylam.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"","article_id":"1184756636","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184756636","pubTimestamp":1785412954,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Alnylam Pharmaceuticals (ALNY) shares tumbled 7.45% in pre-market trading on Thursday after the company reported second-quarter revenue that fell short of analyst expectations.The biotech firm posted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"股票跟踪 | Alnylam Pharmaceuticals 第二季度收入未达到预期，盘前股价暴跌 7.45%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"Alnylam Pharmaceuticals (ALNY) shares tumbled 7.45% in pre-market trading on Thursday after the company reported second-quarter revenue that fell short of analyst expectations.The biotech firm posted revenue of $1.29 billion for the quarter, missing the consensus estimate of $1.323 billion according to Ibes data. The top-line miss appeared to overshadow the company's operating income figures, which were also released alongside the revenue report.Investors reacted swiftly to the shortfall, driving the stock sharply lower in early trading. The decline highlights the market's sensitivity to revenue growth metrics for high-valuation biotech companies like Alnylam.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}